�Challenges in the management of chronic hepatitis E in immunocompromised patients: reactivation after treatment with ribavirin�

Chronic HEV infection is a significant cause of morbidity and mortality in immunocompromised patients, with rapid progression to advanced fibrosis. We present the case of a 71-year-old immunocompromised male with chronic liver disease due to hepatitis E, who experienced several episodes of HEV reactivation despite treatment with ribavirin. Thus, the treatment of the infection involves a challenge due to the lack of validated therapeutic options and the risk of viral reactivation after stopping treatment.